Abstract
Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase that plays a key role in tumor cell proliferation and in the inhibition of apoptosis, and therefore is a potential target for the treatment of cancer. The blockade of IGF-1R kinase activity by small molecule binding to the catalytic domain of the receptor offers promise for the future and this review summarizes the patent literature from 2000 to early 2006.
Acknowledgements
The authors wish to thank M Lakshmanan for providing some relevant articles, R Sivakumar for his help in collecting the articles, and D Vir and his group from the Intellectual Property Department for their support.